Soluble plasma programmed death 1 (PD-1) and Tim-3 in primary HIV infection

被引：26

作者：

Zilber, Eva ^{[1
]}

Martin, Genevieve E. ^{[1
]}

Willberg, Christian B. ^{[1
,2
]}

Fox, Julie ^{[3
,11
]}

Nwokolo, Nneka ^{[4
]}

Fidler, Sarah ^{[5
,6
,9
]}

Frater, John ^{[1
,2
,7
,10
]}

Lever, Andrew ^{[8
]}

Wills, Mark ^{[8
]}

Weber, Jonathan ^{[9
]}

Fidler, Sarah ^{[5
,6
,9
]}

Frater, John ^{[1
,2
,7
,10
]}

Dorrell, Lucy ^{[10
]}

Malim, Mike ^{[11
]}

Fox, Julie ^{[3
,11
]}

Gupta, Ravi ^{[12
]}

Jolly, Clare ^{[12
]}

机构：

[1] Univ Oxford, Nuffield Dept Med, Oxford, England

[2] Natl Inst Hlth Res Biomed Res Ctr, Oxford, England

[3] Guys & St Thomas NHS Trust

[4] Chelsea & Westminster Hosp, London, England

[5] Imperial Coll, Wright Fleming Inst, Div Med, London, England

[6] Imperial Coll, Natl Inst Hlth Res, Biomed Res Ctr, London, England

[7] Oxford Martin Sch, Oxford, England

[8] Univ Cambridge, Cambridge, England

[9] Imperial Coll, London, England

[10] Univ Oxford, Oxford, England

[11] Kings Coll London, London, England

[12] UCL, London, England

来源：

AIDS | 2019年 / 33卷 / 07期

关键词：

T-CELLS; EXPRESSION;

D O I：

10.1097/QAD.0000000000002165

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Soluble forms of the coinhibitory receptors programmed death 1 (PD-1) and Tim-3 exist, but their relationship with T-cell surface expression remains unclear. When measured by an enzyme-linked immunosorbent assay in plasma, soluble PD-1, and soluble Tim-3 were elevated during primary HIV infection, decreased on antiretroviral therapy to levels found in controls, and correlated with cell surface expression. We conclude that soluble PD-1 and soluble Tim-3 are easy to measure biomarkers of immune exhaustion which potentially eliminate the need for flow cytometry.

引用

页码：1253 / 1256

页数：4

共 50 条

[41] The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor
Brinch, Charlotte Margareta
Hogdall, Estrid
Junker, Niels
Moeller, Holger Jon
Sandfeld-Paulsen, Birgitte
de Heer, Pieter
Penninga, Luit
Rossen, Philip Blach
Krarup-Hansen, Anders
Aggerholm-Pedersen, Ninna
CANCERS, 2022, 14 (23)
[42] Programmed death-1 (PD-1) Expression in Sezary Syndrome
Wehkamp, U.
Oschlies, I
Brasch, J.
Klapper, W.
Weichenthal, M.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 (09): : 922 - 922
[43] Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics
Cassol, Clarissa A.
Owen, Dwight
Kendra, Kari
Braga, Juarez R.
Frankel, Wendy L.
Arnold, Christina A.
HISTOPATHOLOGY, 2020, 77 (02) : 240 - 249
[44] Increased Tim-3 Expression on T Cells in Chronic HIV-1 Infection
Addo, M. M.
Wen, F.
Meier, A.
Streeck, H.
Alter, G.
Altfeld, M.
Anderson, D. E.
Hafler, D. A.
Walker, B. D.
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 : 129 - 129
[45] Dysregulation of Tim-3 Expression on NK Cells in Chronic HIV-1 Infection
Jost, S.
Moreno-Nieves, U. Y.
Reardon, J.
Toth, I.
Piechocka-Trocha, A.
Alter, G.
Altfeld, M.
Addo, M. M.
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (10) : A65 - A65
[46] Investigation of immune checkpoint molecules (CTLA-4, PD-1, PD-L1, Tim-3) expressions in preeclampsia: A comparative study of membranous and soluble forms
Parhizkar, Forough
Soltani-Zangbar, Mohammad Sadegh
Shekari, Najibeh
Hajiesmailpoor, Zanyar
Parsania, Sara
Aghebati-Maleki, Ali
Aghebati-Maleki, Leili
HUMAN IMMUNOLOGY, 2025, 86 (03)
[47] In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
Reddy, Vishwanatha R. A. P.
Mwangi, William
Sadigh, Yashar
Nair, Venugopal
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2019, 9
[48] Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Expression in Aggressive Pediatric Lymphomas
Coffey, Amy M.
Curry, Jonathan L.
Marcogliese, Andrea N.
Tetzlaff, Michael T.
Kamdar, Kala
Elghetany, Mohamed T.
Curry, Choladda V.
LABORATORY INVESTIGATION, 2017, 97 : 344A - 344A
[49] Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)
Falchook, Gerald Steven
Ribas, Antoni
Davar, Diwakar
Eroglu, Zeynep
Wang, Judy S.
Luke, Jason J.
Hamilton, Erika P.
Di Pace, Brian
Wang, Tianli
Ghosh, Srimoyee
Dhar, Arindam
Borgovan, Theo
Waszak, Angela
LoRusso, Patricia
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[50] Serum Concentrations of TIM-3, LAG-3, and PD-1 in Patients with Hemorrhagic Fever with Renal Syndrome
Safranko, Zeljka Macak
Jakopec, Lana
Svagusa, Karla
Krajinovic, Lidija Cvetko
Tomasovic, Domagoj
Lukic, Ljiljana
Markotic, Alemka
LIFE-BASEL, 2024, 14 (05):

← 1 2 3 4 5 →